Clinical Research Protocol and Proposal Writing
Pubrica writes clinical research protocols and funder proposals for physicians, surgeons and clinical research teams. Our subject-specialist medical writers prepare the protocol to SPIRIT 2025 for trials, assemble the full ethics submission set around it, including the participant information sheet, consent form, data protection impact assessment and investigator documents, and complete the funder’s annexes to its format. Ethics submissions are most often delayed by these supporting documents rather than by the protocol, so we prepare and check them together. The investigator retains responsibility for the submission.
Protocol written to SPIRIT 202534 of 34 items
Information sheet at the reading level asked forTested
Sample size with its assumptions statedJustified
Registration record drafted before enrolmentProspective
Insurance and CVs requested from the startFrom the start
Idea → design → protocol → the set → committee → approval
- Design settled first
- Sample size justified
- Written to SPIRIT 2025
- The complete submission set
- Version-controlled
Service Scope
Protocol and Proposal Writing Services
Most applicants need the protocol plus two or three of the other services. Each service can be commissioned individually, so you pay only for the documents you need.
Who We Serve
Who We Support with Protocol Writing
We support six groups of applicants. All of them work to fixed committee meeting dates alongside continuing clinical commitments.
Compliance and Standards
Four Regulatory and Reporting Frameworks for Clinical Protocols
Two of these frameworks have changed within the last two years, and one changes again in January 2027. We write to the current versions, because citing a superseded version is visible to reviewers and costly to correct after submission.
SPIRIT 2025 (the structure of a trial protocol)
Revised in 2025 alongside CONSORT and published simultaneously in five journals. It sets out thirty-four items plus the timeline figure, covering administrative information, rationale and objectives, design, participants and interventions, outcomes, sample size, allocation and blinding, data collection and management, statistical methods, monitoring, ethics and dissemination. A protocol written to SPIRIT provides much of the structure of the eventual CONSORT 2025 paper, and both guidelines are published at consort-spirit.org.
ICH E6(R3) (good clinical practice, revised in 2025)
The Principles and Annex 1 were adopted by ICH and the CHMP on 23 July 2025 and replace E6(R2), so a protocol that cites E6(R2) as the current standard is out of date. Annex 2, which covers pragmatic and decentralised trial designs, reached Step 4 in June 2026 and applies in the EU from 15 January 2027; a consolidated version of all three parts was published in July 2026. R3 is more proportionate than R2: it requires quality management focused on the risks that matter to participants and to the reliability of the results, rather than uniform procedures applied everywhere.
The Declaration of Helsinki (revised October 2024)
Most recently revised at the World Medical Association General Assembly in Helsinki in October 2024, after a thirty-month process. The revision strengthened two areas: participant-centred inclusion, respect and protection, covering vulnerability, community engagement, global justice, informed consent and the language used about participants; and research beneficence and value, covering scientific rigour and the equitable distribution of benefits, risks and burdens. A protocol that cites the 2013 Fortaleza version as current is citing a superseded document.
Trial registration (prospective registration required)
The ICMJE requires prospective registration in a WHO primary registry or on ClinicalTrials.gov as a condition of consideration at member journals, and the registration date is public and permanent. Registration must take place before the first participant is enrolled, not before the paper is submitted; retrospective registration cannot be reversed and is a common reason for journals to decline a paper. The registry depends on the jurisdiction: CTRI in India, ISRCTN or ClinicalTrials.gov in the UK alongside HRA approval, ClinicalTrials.gov in the United States, and the EU Clinical Trials Information System under Regulation 536/2014 for trials in member states.
Responsible Use of AI
Responsible Use of AI in Protocol Writing
A protocol defines what will be done to participants and what will be analysed. Each statement is a commitment by the investigator and is approved by the committee, so clear attribution of any AI use is essential.
Why We Do Not Publish AI Accuracy Figures
Accuracy figures for AI tools are usually reported by the companies that sell them.
Pubrica therefore does not quote its own accuracy figure, because it would carry the same conflict of interest. Instead, we tell you which tool was used on your project, at which stage, and what a specialist changed afterwards.
Our Process
How Our Protocol and Proposal Writing Process Works
Ethics committees meet monthly, institutional signatures can take two weeks and insurance confirmations can be slow to arrive. We plan the timeline at the outset, because many submission delays result from scheduling rather than from scientific issues.
Research Question, Study Design and Submission Timeline
Completed before we provide a quote. We establish what you want to find out, which design can answer the question, and the actual deadlines: the committee’s meeting and paper deadline, the funder’s call and any planned staff changes. At this stage we also tell you if the design cannot answer the question, as it is much easier to change at this point than at review.
Objectives, Hypotheses and Sample Size
Objectives are numbered and testable, and the sample size is justified. We state every assumption: the expected effect and its source, the variance, the allowance for attrition, the significance level and the power. A committee can then discuss a specific assumption rather than query an unexplained number.
Protocol Writing to the Required Structure
We write to SPIRIT 2025 for a trial, ISO 14155 for a device investigation and the STROBE items for observational work. The protocol covers background and rationale, design, participants, interventions, outcomes with their instruments and time points, data collection, the statistical analysis plan, monitoring and dissemination. Every page carries a version number and date so that amendments remain traceable.
Supporting Submission Documents
We prepare the participant information sheet, consent form, assent form where children are involved, data management plan, case report form and privacy notice. These are written alongside the protocol and checked against each other. The most common committee query is that the information sheet describes a different study from the protocol, usually because the design changed and only one document was updated.
Funder Annexes and Trial Registration
We follow the funder’s format, budget heads, page limits and scoring criteria. This includes an NIH Specific Aims page, a Horizon Europe impact section, an ICMR budget on the prescribed heads and an NIHR plain English summary. We also draft the registration record, ready to be made public before the first participant is enrolled.
Second Review and Committee Query Response
A second reviewer who did not write the documents checks them against the committee’s checklist. When the query letter arrives, as it does for most submissions, we draft a point-by-point response, with every protocol amendment version-controlled so that the committee can see exactly what changed between submission and resubmission.
Request a Free Protocol Feasibility Assessment
Within two business days and at no cost, we assess whether the design can answer the question, what the submission set will contain in your jurisdiction, how long it will take to assemble and whether your committee date is realistic. An early check of the committee date helps you avoid missing a meeting cycle.
Please send the committee’s forms and guidance notes at the start. Most ethics committees publish a house format, and writing to it from the outset prevents the inconsistencies that arise when a protocol written to a generic template is later adapted to a local form. Inconsistency between the protocol and the information sheet is the query committees raise most often.
Ethics Submission Requirements
Ethics Submission Documents Beyond the Protocol
Ethics committees usually require several documents in addition to the protocol, and some of them depend on colleagues or offices outside the study team. The builder below lists the documents for your study design and jurisdiction, estimates how long they take to assemble and indicates whether your deadline is realistic.
01
Every document your committee will ask for, the registration route for your region, the annexes your funder adds, and whether your date holds.
Runs in your browser; no data is sent9
Items in the submission set
8 wk
To assemble and write
Tight
Against your date
Structural guideline: SPIRIT 2025. SPIRIT was revised in 2025 alongside CONSORT and now has 34 items plus the timeline figure. It is the protocol counterpart of CONSORT, both are published at consort-spirit.org, and a protocol written to SPIRIT provides much of the structure of the eventual CONSORT paper.
Your timeline. Tight. 8 weeks against roughly 8. The timeline is achievable only if institutional signatures and the insurance confirmation are requested at the start rather than at the end.
The submission set
Registration
What your funder adds
How the submission set is determined. The set is built from the design and the jurisdiction you selected. Structural guidelines: SPIRIT 2025 for trial protocols at consort-spirit.org, ISO 14155 for device clinical investigation plans, STROBE and RECORD as anchors for observational and routine-data studies, SRQR or COREQ for qualitative work. Good clinical practice is ICH E6(R3): its Principles and Annex 1 were adopted by ICH and the CHMP on 23 July 2025 and replace E6(R2), and Annex 2, covering pragmatic and decentralised designs, reached Step 4 in June 2026 and applies in the EU from 15 January 2027. The ethical framework is the Declaration of Helsinki, most recently revised at the World Medical Association General Assembly in Helsinki in October 2024. This is a planning aid, not regulatory advice, and it is not exhaustive. Your ethics committee, your competent authority and your institution set the actual requirements, and they differ. The investigator and the sponsor hold responsibility for the ethics submission and for the consent process. We draft documents to your instructions; that responsibility remains with the investigator and the sponsor.
Responsibility for the Ethics Submission
The investigator and the sponsor are responsible for the ethics submission. We write documents to your instructions and to the committee’s format. The scientific and ethical content is yours, the approval is granted to you, and the consent process, including the conversation with the participant, the assessment of capacity and the judgement that the participant has understood, is a clinical responsibility of the investigator. Our role is to make the documents clear, complete and consistent with each other, which is where many submissions fall short. We do not take on the investigator’s or the sponsor’s duty, and no writing service can.
Common Protocol Scenarios
Six Common Protocol and Ethics Submission Scenarios
These are six common types of protocol project. For each, we describe the issue that most often determines whether the submission is approved at first review.
A cardiologist preparing an investigator-initiated trial
The protocol is written to SPIRIT 2025, and the science is usually sound. The key issue is the sample size: a committee treats an unjustified number as a feasibility risk, because a trial that cannot reach its recruitment target exposes participants to research that cannot answer its question. We state every assumption in the calculation, including the expected effect, its source, the variance and the attrition allowance, so that reviewers can assess each one. The second issue is the monitoring plan: an investigator-initiated trial still needs one, proportionate to risk, and it is often omitted when no sponsor requires it.
An orthopaedic surgeon evaluating a technique
The main question is the choice of comparator. Comparing a new technique with your own historical series is a single-centre before-and-after comparison, confounded by the learning curve, case selection and other changes over time. Committees will ask about this, and the appropriate options are a concurrent comparison, a prospective registry with pre-specified outcomes, or an explicit statement that the design supports a hypothesis rather than a conclusion. The learning curve must also be stated in the protocol as a factor.
An ENT specialist submitting a device study
A clinical investigation plan differs from a clinical trial protocol. It is written to ISO 14155, accompanies the risk analysis to ISO 14971 and the instructions for use, and under the EU MDR is submitted to a competent authority as well as an ethics committee. Applicants who prepare it as an academic protocol are asked for the technical documentation, and the resulting delay can be months rather than weeks.
A resident turning a thesis into a funder-ready protocol
A thesis protocol is written for a supervisor and a university committee, whereas a funder’s protocol is written to compete. The differences are structural: the background is condensed to a page that establishes the research gap, the objectives become numbered and testable, the methods gain a timeline and a budget, and a feasibility case is added. This requires a rewrite rather than a reformat, and it is best done before the thesis version is finalised.
A neurologist proposing an observational cohort
There is no SPIRIT equivalent for observational studies, which is why their protocols are often under-specified and queried more often than trial protocols. We write the protocol against the STROBE items so that key decisions are made in advance: how confounders will be selected, how missing data will be handled, which analyses are pre-specified and which are exploratory, and the length of the follow-up window. Committees look for a pre-specified analysis plan in every cohort study.
A dental surgeon proposing a public health intervention
Community and behavioural interventions raise consent questions that individual clinical research does not: who consents when the unit of allocation is a school, clinic or village, how people in the setting who did not consent are protected, and how the intervention will be withdrawn if it proves effective. Addressing these questions in the protocol, rather than in a query response, can avoid additional committee meetings.
Our Experts
Your Protocol Writing Team
A named team of medical writers, statisticians and subject specialists stays with your project from scoping to delivery. Your project coordinator introduces each team member by name before work begins, and the handover records who completed each stage.
Reviews the scientific content for accuracy and confirms that each conclusion is supported by the evidence. Each expert is matched to your field.
Writes the manuscript or document against the applicable reporting guideline and the target journal or funder requirements, with every statement traceable to its source.
Checks that statistical methods, tables and conclusions are consistent with the analysis plan and that the analysis can be reproduced.
Checks the finished work independently against the agreed scope and the applicable checklist. Findings are logged and resolved before delivery.
Sample Work
Sample Work: Protocol Summary and Ethics Submission Set
A committee focuses on four areas of a protocol package: the sample size justification, the information sheet, the consistency between documents and the risk-benefit statement. Use the tabs to view each area, then open the full sample below to read a complete protocol summary.
Protocol package · extract
Investigator-initiated trial · SPIRIT 2025 · 11 documents
Sample size · the information sheet · consistency · risk and benefit
- The number
- 212 participants, 106 per arm, before attrition. The justification for this number matters more than the number itself.
- Expected effect, and where it comes from
- A difference of 0.45 standard deviations, taken from two named published trials in a comparable population, both cited. A phrase such as “a clinically meaningful difference” gives reviewers nothing to check.
- Why that effect and not a larger one
- The smallest difference worth detecting is a clinical judgement and must be justified. Powering for a large effect can leave a trial unable to exclude a small but important one.
- Variance assumption
- Standard deviation taken from the same published trials, with a note that the local population may differ and how that would be handled.
- Attrition
- 15%, justified from the site’s own follow-up rates in a comparable study rather than from a convention. Inflated figure: 250.
- Alpha, power and sidedness
- 5% two-sided, 90% power, all stated. One-sided testing is occasionally appropriate and must always be justified.
- Feasibility, checked against the clinic
- 250 participants over 18 months at this site means 14 a month against a clinic that sees 41 eligible patients a month. Stated, with the consent rate assumption given, because a committee reads an unchecked recruitment target as a risk to participants.
Rewritten from grade 13 to grade 7The most common reason a submission is returned
4 inconsistencies, all from one design changeIdentified before submission rather than in the query letter
- Risks, listed individually
- Each with its likelihood, its severity and the action to be taken, rather than a general statement that risks are minimal.
- Procedures beyond routine care
- Named explicitly and separated from routine care, because this distinction defines the burden on the participant.
- Burden in hours
- Six extra visits of roughly forty minutes each, plus travel. The burden is quantified, because “minimal additional burden” reflects the applicant’s judgement rather than the participant’s experience.
- Benefit, stated honestly
- Including where there is no direct benefit to the participant. The Declaration of Helsinki, as revised in October 2024, places particular weight on the equitable distribution of benefits, risks and burdens.
- Stopping rules
- What would cause the trial to stop early, who decides and on what data. Stopping rules allow a trial to respond to harm.
- What happens after it ends
- Whether participants who benefited will continue to have access, and how results will be returned to them. Committees increasingly ask for this, and first drafts rarely include it.
Redacted extract · study and site details changedSecond-reader review, before submission
A committee reviews these four areas closely and may raise queries on each. Use the tabs to view each area.
The consistency tab shows the most frequent problem. Four inconsistencies between documents resulted from a single design change in draft four that was applied only to the protocol. This is a common outcome when eleven documents are written by four people over six weeks.
The information sheet is the most common reason a submission is returned. The issue is usually readability rather than content. A sheet written at grade 13 for a population that reads at grade 7 does not support informed consent, and committees increasingly raise this.
Request a sample and we will send a protocol package prepared for a study like yours, with the same design, jurisdiction and committee format.
Research proposal · sample protocol summary
Protocol summary and submission set — investigator-initiated trial
A real protocol package with the condition, the intervention, the institution and all identifying details changed. The structure, second-reader findings and document list are as delivered. On request, we will send a sample prepared for a study like yours.
1Design, in the terms SPIRIT asks for
| SPIRIT element | As written |
|---|---|
| Design | Parallel-group, two-arm, 1:1, superiority. The design is named explicitly, as SPIRIT requires, rather than left to be inferred from the methods. |
| Setting | Two secondary care sites, with usual care at each described, because differences in usual care are a common source of unexplained variation. |
| Eligibility | Nine inclusion and six exclusion criteria, each defined operationally. “Significant comorbidity” is replaced with a defined index and threshold so that screening staff can apply the criterion consistently. |
| Interventions | Dose, route, schedule, duration, who administers, what counts as a protocol deviation, and the criteria for discontinuing or modifying. |
| Primary outcome | One primary outcome, with its measurement instrument, time point and assessor, who is blinded to allocation because the outcome is subjective. |
| Secondary outcomes | Six, ranked, each with an instrument and time point. They are ranked at this stage because the registered record is used to check the eventual paper for outcome switching. |
| Allocation | Computer-generated sequence, stratified by site, in permuted blocks of varying size, with concealment by a central web system. Methods reviewers check this description first. |
| Blinding | Participants, outcome assessors and the analyst are blinded. The treating clinician cannot be blinded; this is stated, together with the measures taken to limit its effect. |
| Timeline figure | The SPIRIT schedule of enrolment, interventions and assessments, presented as a figure. It is often omitted, although it shows the committee the visit burden at a glance. |
2Sample size, with the workings
| Assumption | Value | Where it came from |
|---|---|---|
| Smallest difference worth detecting | 0.45 SD | Two named published trials in a comparable population, both cited, with the difference justified as a clinical judgement. |
| Standard deviation | From the same trials | With a note that the local population may differ and what would be done if the observed variance were larger. |
| Alpha | 5%, two-sided | Stated. One-sided testing is occasionally appropriate and must always be justified. |
| Power | 90% | Stated, with the consequence of 80% given for comparison so the committee can see the trade. |
| Analysable sample | 212 (106 per arm) | The output of the calculation; the assumptions behind it matter more. |
| Attrition allowance | 15% | From the site’s own follow-up rates in a comparable study, not from convention. |
| Target recruitment | 250 | Inflated figure. |
| Feasibility check | 14 per month for 18 months | Against a clinic seeing 41 eligible patients a month, with the assumed consent rate stated. Committees treat an unchecked recruitment target as a risk to participants. |
3The submission set, as filed
| # | Document | Note |
|---|---|---|
| 1 | Protocol, v1.3, dated | SPIRIT 2025, 34 items, version and date in the footer of every page. |
| 2 | Participant information sheet, v1.3 | Rewritten from grade 13 to grade 7 as measured by SMOG, against the committee’s stated target. |
| 3 | Informed consent form, v1.3 | Separate document, with a copy for the participant and a separate optional section for sample storage. |
| 4 | GP or usual-clinician notification letter | Required by this committee and often overlooked by applicants. |
| 5 | Case report form | Submitted with the protocol, because the committee checks that the data collected do not exceed what the protocol justifies. |
| 6 | Data management plan | Who holds the data, where, for how long, and what happens at the end of the study. |
| 7 | Privacy notice and lawful basis | Plus a data protection impact assessment, because the processing is high risk. |
| 8 | Monitoring plan | Proportionate to the risk. Investigator-initiated trials still require one, and it is often missing. |
| 9 | Investigator CVs, current and signed | For both sites. Out-of-date CVs lead to query letters and can cost a meeting cycle. |
| 10 | Insurance and indemnity confirmation | Requested in week one, because it took eleven days to arrive. |
| 11 | Registration record, drafted | Ready to be made public before the first participant is enrolled. Registration is prospective, permanently visible and cannot be reversed. |
4Second-reader findings, before submission
| Finding | Severity | Resolution |
|---|---|---|
| Follow-up stated as 12 months in the protocol and 6 in the information sheet | Critical | Design extended in draft four; only the protocol updated. Reconciled to 12 across all documents. |
| Blood volume 20 ml in the protocol, 15 ml on the consent form | Critical | A participant consents to what the form says. Reconciled to 20 ml, with the number of draws and the study total added to the information sheet. |
| Six secondary outcomes in the protocol, four in the registration draft | Major | Reconciled before registration. The registered record is the reference for outcome switching. |
| Data retention 5 years in one document, 10 in another | Major | Reconciled to the institution’s retention policy, which the committee compares both against. |
| Information sheet at grade 13 | Major | Rewritten to grade 7 with the instrument and target recorded in the submission. |
| “Significant comorbidity” as an exclusion criterion | Minor | Replaced with a defined index and threshold that screening staff can apply. |
| No stopping rules | Major | Added, specifying who decides and on what data, so that the trial can respond to harm. |
Seven findings were identified. Six resulted from one design change made midway through drafting and applied to some documents but not others. An independent second review by someone who did not write the package is designed to identify such issues.
5Limitations of This Package
The package does not obtain approval for you, and it does not transfer your responsibility. The investigator and the sponsor are responsible for the ethics submission and for the consent process, including the conversation with the participant, the assessment of capacity and the judgement that the participant has understood. This is a clinical responsibility that a writing service cannot assume.
We cannot guarantee approval at first review. Most submissions receive a query letter, including well-prepared ones. A well-assembled package helps ensure that queries are substantive rather than administrative, which can allow approval by chair’s action rather than at another full meeting.
Prepared by Pubrica. Pubrica is a trading name of Guires®, registered in England, Wales and India.
Request this samplePackages
Protocol and Proposal Writing Packages
Prices depend on the study design, the jurisdiction and how much of the submission set you need.
Protocol writing
Residents, fellows and academic researchers with a settled topic and a design already chosen
From $45025–30 pages · 1 site · 1 revision round
Delivery 10–12 business days
- ✓The protocol structured to SPIRIT 2025, or to the STROBE items where observational
- ✓Background, rationale, objectives and methodology
- ✓Referencing in APA, AMA or Vancouver, and language editing
- ✓Originality screening, with every match classified
- ✓Version control set up, so amendments stay traceable
Available as add-ons: sample size, the ethics document set and registration.
View a sample Select BasicProtocol with study design and statistics
Clinicians and early-career faculty who need support with methodology and analysis as well as writing
From $7001 study · sample size and analysis plan · 2 sites
Delivery 12–15 business days
- ✓Everything in Basic
- ✓Design consultation to confirm the design can answer the question
- ✓Hypotheses, variables and outcome instruments with their time points
- ✓Sample size with every assumption stated and its source given
- ✓A statistical analysis plan written before any data exists
- ✓Alignment to ICH E6(R3) and to your committee’s own format
Available as add-ons: the full ethics set, funder annexes and the budget.
View a sample Select AdvancedComplete ethics submission set
Physicians and surgeons preparing for ethics review, an investigator-initiated trial or a funding call
From $1,100up to 11 documents · 1 committee · 1 funder format
Delivery 15–20 business days
- ✓Everything in Advanced
- ✓Participant information sheet and consent form, readability measured against a target
- ✓Data management plan, privacy notice and impact assessment where needed
- ✓Case report form, monitoring plan and the covering application
- ✓Registration record drafted, ready before first enrolment
- ✓Second-reader review across the whole set for cross-document consistency
- ✓Two further revision rounds, and the response to the committee’s query letter
Multi-site and multi-country submissions are quoted separately.
View a sample Select PremiumIndividual services
Grant budget and cost justification
From $1505 business days
Bought on its own, or alongside any tier
Built from the protocol, so that staffing follows the visit schedule and consumables follow the sample count, and justified line by line on the funder’s budget heads.
Individual services
PICO or PICO-T framing
From $753 business days
Bought on its own, or alongside any tier
The research question framed so that it can be searched and tested, with the population, intervention, comparator, outcome and time frame each clearly defined.
Individual services
Defence or panel slide deck
From $1204–5 business days
Bought on its own, or alongside any tier
Built from the protocol, with speaker notes and dedicated slides on the three topics panels focus on: the design, the sample size justification and the feasibility case.
Individual services
Committee query response
From $1805–7 business days
Bought on its own, or alongside any tier
Point-by-point responses, with every protocol amendment version-controlled so the committee can see exactly what changed. A clear response can allow approval by chair’s action rather than at a second full meeting.
Individual services
Scientific translation into English
From $100Quoted on length
Bought on its own, or alongside any tier
Translated by a subject-specialist translator and then edited as a complete document, because standard clinical terminology in one language often has no single equivalent in another.
Individual services
Protocol to manuscript conversion
From $2507–10 business days
Bought on its own, or alongside any tier
A full rewrite, because a protocol describes planned work in the future tense and a paper reports completed work in the past tense, and the differences extend beyond verb tense.
Expedited delivery in 5–7 business days is available where capacity allows and is priced according to capacity rather than urgency. We do not charge more for the same work because your deadline is close, and if a deadline cannot be met we will tell you before accepting the project.
Quality Assurance
Our Service Commitments and Limitations
Ethics approval and funding decisions are made by committees and panels. These are our commitments and limitations, set out before you commission any work.
Our revision commitment
Revision Support Until Agreed Requirements Are Met
We revise the protocol and the submission set until they meet the brief and the committee’s format, with no limit on revision rounds within the agreed scope. The response to the first query letter is included in the Premium tier.
01
Query letter responses included
Most submissions receive a query letter, including well-prepared ones. On the Premium tier, the response is included rather than quoted as a new project.
02
Corrections at our cost
If a missed SPIRIT item, a cross-document inconsistency or an outdated form version results from our work, we correct it at no cost within the agreed scope and inform you first.
03
Early notice if a deadline is not achievable
Committee deadlines and funding calls are fixed. If your date is not achievable, we tell you at the quote stage.
04
Version control from the start
Every document is numbered and dated, so that each amendment can be traced and the committee can see exactly what changed. This prevents one of the most common committee queries.
Service limitations. The investigator and the sponsor are responsible for the ethics submission, the conduct of the study and the consent process. We draft documents to your instructions; that responsibility remains with you. We cannot guarantee ethics approval or a funding award, and we do not quote success rates, because those decisions belong to committees and panels. We will not write a protocol for a study that we believe cannot answer its question; instead, we will explain why and recommend a design that can. We will not work backwards from a preferred sample size to fit the recruitment you can manage, and where the achievable sample is smaller than the question requires, we will explain the implications for the study’s conclusions. We will not draft a consent document that softens a statement about benefit.
Free feasibility assessment
We assess whether the design can answer the question, what the submission set contains in your jurisdiction, how long it takes to assemble and whether your committee date is realistic, within two business days at no cost and with no obligation. An early check of the date can help you avoid missing a meeting cycle, which in most institutions is four to eight weeks.
Registration before enrolment
We draft the registration record early and remind you to make it public before the first participant is enrolled, which is the only point at which prospective registration is possible. Retrospective registration is permanently visible in the registry, cannot be corrected and is a common reason for ICMJE member journals to decline the eventual paper.
Confidentiality and data handling
A non-disclosure agreement is signed before any material is shared. Unpublished protocols, pilot data and funding applications are held under the UK GDPR on access-controlled systems within a quality management system certified to ISO 9001:2015, retained only as long as the project requires, never used to train any system and never shared outside your project team. We do not accept competing applications to the same funding call.
Current guideline versions checked on every project
Frameworks in this area change regularly. ICH E6(R3) replaced E6(R2) in July 2025, its Annex 2 for pragmatic and decentralised designs applies in the EU from January 2027, SPIRIT was revised in 2025 and the Declaration of Helsinki was revised in October 2024. We confirm the current version of each framework at the start of every project, and if we find an outdated citation in our own work we tell you.
Client Stories
Client Feedback on Protocol and Proposal Projects
Paraphrased from client feedback.
“Four of our eleven documents disagreed with each other. All four came from one design change that only got applied to the protocol.”
“They told me at the quote stage that my committee date was not achievable. I did not want to hear it and it was correct.”
“Our information sheet tested at grade thirteen. We had all read it and none of us noticed, because we could read it.”
FAQs
Protocol and Proposal Writing FAQs
If you are unsure whether your design can answer your question or what your committee will require, please ask an expert. No quote is required.
For a trial, the 34 items of SPIRIT 2025 plus its timeline figure: administrative information with the registration details and the version, the background and rationale, the objectives, the design named explicitly, the setting and eligibility criteria as they will be applied, the interventions with their dose, route, schedule and discontinuation criteria, the outcomes with their instruments and time points, the sample size with its assumptions, recruitment, allocation and concealment, blinding, data collection and management, the statistical methods, monitoring and harms reporting, and the ethics and dissemination plans. The two items most often omitted are the schedule of enrolment, interventions and assessments, which SPIRIT requires as a figure and which shows the committee the visit burden at a glance, and the stopping rules. There is no SPIRIT equivalent for observational studies, so we write those protocols against the STROBE items, which ensures that key decisions are made before analysis.
By stating every assumption and its source rather than presenting a number alone. A committee or reviewer can assess a 0.45 standard deviation effect taken from two named trials far more readily than a bare figure of 212. The justification should include the smallest difference worth detecting, argued as a clinical judgement with its source; the variance and its source; the significance level and whether the test is one- or two-sided, with a justification if it is one-sided; the power; and the allowance for attrition, based on your own site’s figures rather than convention. It should then include a feasibility check, which is often missing: if the inflated target is 250 over eighteen months at a clinic seeing 41 eligible patients a month, state this together with the assumed consent rate. Committees treat an unchecked recruitment target as a risk to participants, because a trial that cannot recruit exposes people to research that cannot answer its question. Our free sample size calculator performs the calculation; the protocol provides the justification.
Most submissions receive a query letter, including well-prepared ones. Queries usually arise from four causes. The participant information sheet is written above the reading level of the population; this is the most common cause and an ethical issue rather than a stylistic one, because a sheet participants cannot read does not support informed consent. Two documents disagree, usually because the design changed and only one was updated. The sample size is stated without a justification. An administrative item is missing or out of date, such as an unsigned CV, an unnumbered protocol version or an outstanding insurance confirmation. Three of these four causes can be prevented by a second reviewer checking the set against the committee’s checklist before submission.
We draft the document to your instructions and to your committee’s format, and we measure its readability against a stated target. We do not take on the responsibility for consent, and no writing service can. The investigator and the sponsor are responsible for the ethics submission, and the consent process, including the conversation with the participant, the assessment of capacity and the judgement that the participant has understood what they are agreeing to, is a clinical responsibility of the clinician taking consent. We state this clearly because responsibility for consent forms and risk-benefit analyses is often left undefined, which creates a risk for the client. Where we draft a document, the covering application states this, in the same way as an acknowledgement in a paper.
A protocol is the operating document: it sets out what will be done, to whom, when and by whom, and what happens if something goes wrong. It is read by an ethics committee, a regulator and later the study team. A proposal is a competitive document: it explains why the question matters, why this team is suited to it, why the work is timely and what it will cost. It is read by a funding panel scoring against published criteria. The two share a methods section but differ in most other respects: the proposal condenses the background to a page that establishes the research gap, adds a timeline, a budget and a case for the team, and is written to an enforced page limit. Most clinical studies need both, and converting one into the other requires a rewrite. A common mistake is submitting a protocol to a funder, because a protocol does not explain why the research matters.
Read the call and the scoring criteria before writing, and address the criteria in the order and with the weight the funder gives them. Horizon Europe scores Excellence, Impact, and Quality and Efficiency of the Implementation, in that order, and clinical proposals often lose marks on impact because they do not describe a clear pathway to impact. NIH reviewers read the Specific Aims page first and assess the rest of the application against it, so it should be drafted first and revised last; the data management and sharing plan has been required since the 2023 policy and is often underdeveloped. NIHR requires evidence of patient and public involvement, including who was involved, when and what changed as a result, together with a plain English summary written in genuinely plain language. ICMR, DBT and DST prescribe their formats and budget heads, and errors on these forms cause many rejections. Every funder enforces its page limits, often automatically.
Before the first participant is enrolled; registration cannot be corrected later. The ICMJE requires prospective registration in a WHO primary registry or on ClinicalTrials.gov as a condition of consideration at member journals, and the registration date is public and permanent. A trial registered after enrolment begins carries that record permanently, and editors will see it when you submit the paper. The registry depends on your location: the Clinical Trials Registry – India, ClinicalTrials.gov in the United States, ISRCTN or ClinicalTrials.gov in the UK alongside Health Research Authority approval, and the EU Clinical Trials Information System under Regulation 536/2014 for trials in member states. Register the outcomes you intend to report, in the order you intend them, because the registered record is used to check your eventual paper for outcome switching.
ICH E6(R3) is current: its Principles and Annex 1 were adopted by ICH and the CHMP on 23 July 2025 and replace E6(R2). Annex 2, which covers pragmatic and decentralised trial designs, reached Step 4 in June 2026 and applies in the EU from 15 January 2027, with a consolidated version of all three parts published in July 2026. A protocol written in 2026 that cites E6(R2) as the current standard is out of date, and regulatory reviewers will notice. The practical difference is proportionality: R3 requires quality management focused on the risks that matter to participant safety and the reliability of the results, rather than uniform procedures applied regardless of risk. For investigator-initiated studies, this supports a monitoring plan proportionate to a low-risk study.
No, and we do not quote success rates. Ethics approval is a committee’s decision and a funding award is a panel’s decision. We commit to what is within our control: a submission set that is complete, internally consistent, written to the committee’s format and to the current versions of the governing frameworks, and checked by a second reviewer against the committee’s checklist before submission. This helps ensure that queries are substantive rather than administrative, and substantive queries can often be resolved by chair’s action rather than another full meeting. We will also tell you if we believe a design cannot answer its question, even if this means the project does not proceed.
Related services
Related Research and Writing Services
Services that support your study before the protocol is written and after the study is complete.
1BEFORE THE PROTOCOLthe question and the design
Experimental designStudy design support before the protocol is written. Clinical literature reviewA literature review that establishes the research gap your study addresses.Insights
Further Reading on Research Design and Publication
Three articles from our library on structuring and publishing research.
Request a Free Feasibility Assessment
We assess whether the design can answer the question, what your submission set contains, how long it takes to assemble and whether your committee date is realistic, within two business days, at no cost and with no obligation.